Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.69 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.69 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27674003 | 0.91 | CYP4F2 (0.65) | CYP4F2CYP4A11CDYLKDM4EALDH1A1 | |
| SCHEMBL6677814 | 0.86 | CDYL (0.63) | CYP4F2CYP4A11CDYLKDM4EKMT2A | |
| SCHEMBL31505091 | 0.85 | CYP4F2 (0.55) | CYP4F2CYP4A11CDYLKDM4EALDH1A1 | |
| SCHEMBL7062411 | 0.85 | CDYL (0.55) | CYP4F2CYP4A11CDYLKDM4EALDH1A1 | |
| SCHEMBL69660 | 0.85 | CYP4F2 (0.86) | CYP4F2CYP4A11CDYLKDM4EALDH1A1 | |
| SCHEMBL845701 | 0.84 | KMT2A (0.62) | CYP4F2CYP4A11KDM4EALDH1A1KMT2A | |
| SCHEMBL30498970 | 0.84 | CDYL (0.60) | CDYLKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL6615856 | 0.84 | CDYL (0.60) | CDYLKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL29729685 | 0.84 | KMT2A (0.62) | CYP4F2CYP4A11KDM4EALDH1A1KMT2A | |
| SCHEMBL4988468 | 0.84 | CDYL (0.52) | CYP4F2CYP4A11CDYLKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20130310320-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130123253-A1 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2013-05-16 | — | — | US | disclosed |
| US-8378099-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACUETICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8168635-B2 | 2-(aminomethyl)-5-phenyltetrahydrofuran; 4-(3,4-Dimethoxyphenyl)-2-[5-(2-{5-[2-(5-fluoro-2-methoxyphenyl)-ethyl]-tetrahydrofuran-2-yl}-ethylamino)-pentyl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one; dual inhibitor of serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme activity | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110306560-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-8003791-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090247731-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-0788360-B3 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARM INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7531526-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-5587379-A | CONTROLLING INSECTS IN AGRICULTURAL CROPS | FMC CORPORATION (US) | 1996-12-24 | — | — | US | disclosed |
| US-5521192-A | TOBACCO BUDWORM, CABBAGE LOOPER, BEET ARMYWORM | FMC CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
| WO-1996013266-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
| EP-0671881-A4 | INSECTICIDAL 5-SUBSTITUTED-2,4-DIAMINOPYRIMIDINE DERIVATIVES. | FMC CORP (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0671881-A1 | INSECTICIDAL 5-SUBSTITUTED-2,4-DIAMINOPYRIMIDINE DERIVATIVES | FMC CORPORATION (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994012032-A1 | INSECTICIDAL 5-SUBSTITUTED-2,4-DIAMINOPYRIMIDINE DERIVATIVES | FMC CORPORATION (US) | 1994-06-09 | — | — | WO | disclosed |
| US-4523015-A | Process and nitroaminopyrimidone intermediates for histamine H2 -antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-06-11 | — | — | US | disclosed |
| EP-0004793-B1 | 2-NITRO AMINOPYRIMIDONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE TO PREPARE 2-AMINOPYRIMIDONE DERIVATIVES WHICH HAVE HISTAMINE H2-ANTAGONIST ACTIVITY | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-12-30 | — | — | EP | disclosed |
| US-4227000-A | Intermediates in the process for making histamine antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-10-07 | — | — | US | disclosed |
| EP-0004793-A2 | 2-nitro aminopyrimidone derivatives, a process for their preparation and their use to prepare 2-aminopyrimidone derivatives which have histamine H2-antagonist activity | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | CYP4F2 3071/4885CYP4A11 2848/4885CDYL 96/4885 |
| US-20110306560-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | CYP4F2 3071/4885CYP4A11 2848/4885CDYL 96/4885 |
| US-20090247731-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | CYP4F2 3071/4885CYP4A11 2848/4885CDYL 96/4885 |
| US-20130123253-A1 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | GAP43, SLC18A2, CHRNA6 | CYP4F2 2497/4885CYP4A11 2970/4885CDYL 2933/4885 |
| US-20130310320-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | CYP4F2 3071/4885CYP4A11 2848/4885CDYL 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.